The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19

The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19

Abstract Recently, we reported the phase II portion of the adaptive phase II/III PANAMO trial exploring potential benefit and safety of selectively blocking C5a with the monoclonal antibody vilobelimab (IFX‐1) in patients with severe coronavirus disease 2019 (COVID‐19). The potent anaphylatoxin C5a...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexander P. J. Vlaar (Author), Endry H. T. Lim (Author), Sanne deBruin (Author), Simon Rückinger (Author), Korinna Pilz (Author), Matthijs C. Brouwer (Author), Ren‐Feng Guo (Author), Leo M. A. Heunks (Author), Matthias H. Busch (Author), Pieter vanPaassen (Author), Niels C. Riedemann (Author), Diederik van deBeek (Author)
Format: Book
Published: Wiley, 2022-04-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items